KEGG   DRUG: Guselkumab
Entry
D10438                      Drug                                   
Name
Guselkumab (USAN/INN);
Guselkumab (genetical recombination) (JAN);
Tremfya (TN)
Product
Formula
C6402H9864N1676O1994S42
Exact mass
143471.0249
Mol weight
143559.65
Sequence
(Heavy chain)
EVQLVQSGAE VKKPGESLKI SCKGSGYSFS NYWIGWVRQM PGKGLEWMGI IDPSNSYTRY
SPSFQGQVTI SADKSISTAY LQWSSLKASD TAMYYCARWY YKPFDVWGQG TLVTVSSAST
KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY
SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV
FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK
NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG
NVFSCSVMHE ALHNHYTQKS LSLSPGK
(Light chain)
QSVLTQPPSV SGAPGQRVTI SCTGSSSNIG SGYDVHWYQQ LPGTAPKLLI YGNSKRPSGV
PDRFSGSKSG TSASLAITGL QSEDEADYYC ASWTDGLSLV VFGGGTKLTV LGQPKAAPSV
TLFPPSSEEL QANKATLVCL ISDFYPGAVT VAWKADSSPV KAGVETTTPS KQSNNKYAAS
SYLSLTPEQW KSHRSYSCQV THEGSTVEKT VAPTECS
(Disulfide bridge: H22-H96, H144-H200, H220-L216, H226-H'226, H229-H'229, H261-H321, H367-H425, H'22-H'96, H'144-H'200, H'220-L'216, H'261-H'321, H'367-H'425, L22-L90, L139-L198, L'22-L'90, L'139-L'198; Modified residue: L1, L'1 Q=pyroglutamic acid [CPD:C01879]; Glycosylation site: Asn-297, Asn-297'')
  Type
Peptide
Class
Immunological agent
 DG02019  Interleukin inhibitor
Remark
Therapeutic category: 3999
ATC code: L04AC16
Product: D10438<JP/US>
Efficacy
Antipsoriatic, Anti-IL-23 antibody
  Disease
Plaque psoriasis [DS:H01656]
  Type
Monoclonal antibody
Comment
Treatment of inflammatory diseases, psoriasis
Target
IL23A [HSA:51561] [KO:K05426]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  JAK-STAT signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AC Interleukin inhibitors
     L04AC16 Guselkumab
      D10438  Guselkumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunological Agents, Other
   Interleukin Blockers
    Guselkumab
     D10438  Guselkumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D10438  Guselkumab (USAN/INN); Guselkumab (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Immunological agent
  DG02019  Interleukin inhibitor
   D10438  Guselkumab
Drug classes [BR:br08332]
 Immunological agent
  DG02019  Interleukin inhibitor
   D10438  Guselkumab
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Interleukins
    IL23A
     D10438  Guselkumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10438
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10438
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10438
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10438
Other DBs
CAS: 1350289-85-8
PubChem: 172232531
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system